The Department of Endocrinology, 
Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.
- Department of Endocrinology, Bharti Hospital, Karnal, India.
- Department of Endocrinology, Max Hospital, Patparganj, New Delhi, India.
- Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore (TN) -632004, India, and Non Communicable Disease Unit, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
JPMA. The Journal of the Pakistan Medical Association Vol. 72 · Issue 5 · pp. 989-990
PMID 35713074DOI 10.47391/jpma.22-64
Cite This Article
Sanjay Kalra, Saptarshi Bhattacharya, Nitin Kapoor. Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management. JPMA. The Journal of the Pakistan Medical Association. 2022;72(5):989-990. doi:10.47391/jpma.22-64
Abstract
The availability of newer glucose-lowering drugs has created opportunities for comprehensive diabetes care. Two classes of drugs, GLP1RA (glucagon-like peptide 1 receptor agonists), and SGLT2i (sodium glucose cotransporter 2 inhibitors) have demonstrated their efficacy in glucose control as well as cardiovascular risk reduction. While both can be used together, there is an ongoing debate regarding their relative advantages and limitations. We present a clinical perspective to compare and control these two classes of drugs, and promote rational prescription in diabetes praxis.
Keywords
- Canagliflozin
- CV risk reduction
- dapagliflozin
- dulaglutide
- empagliflozin
- GLP1RA
- liraglutide
- obesity
- semaglutide
- SGLT2i.
